Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin in T2DM with Severe Renal Impairment
NCT00800683Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 1356 with Placebo (2 arms). Primary endpoint: HbA1c Change From Baseline at Week 12. Started Dec 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00800683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800683.